PCOD / PCOS and Holistic Wellness

Abstract

Polycystic Ovary Syndrome (PCOS), commonly referred to in Indian clinical and public settings as PCOD (Polycystic Ovarian Disease), is the most common endocrine disorder among women of reproductive age. It affects an estimated 8% to 13% of women in this age group globally, yet approximately 70% of affected women remain undiagnosed worldwide, representing a substantial gap between disease burden and clinical recognition (WHO, 2023).

This paper examines PCOS/PCOD from a holistic wellness perspective while maintaining the primacy of evidence-based diagnosis and appropriate medical care. It reviews global prevalence statistics, the Rotterdam diagnostic criteria, the pathophysiology linking insulin resistance and hyperandrogenism, diagnostic evaluation, red-flag presentations and modern management.

The paper proposes the SR VAIDYA Integrative Framework for PCOS/PCOD Wellness Education, built on early screening, verified diagnosis, individualised lifestyle support and responsible Ayurvedic integration. Ayurvedic and Panchakarma approaches are discussed within clear safety boundaries as complementary wellness measures that must never replace or delay verified diagnosis or evidence-based treatment, including fertility care where relevant.

Keywords: PCOS, PCOD, Polycystic Ovary Syndrome, Insulin Resistance, Hyperandrogenism, Anovulation, Holistic Wellness, Ayurveda, Panchakarma, Lifestyle Medicine, Integrative Health.

01 / Introduction

Introduction

Polycystic Ovary Syndrome was first comprehensively described by Stein and Leventhal in 1935 and has since become recognised as the most common endocrine and metabolic disorder affecting women of reproductive age worldwide.

Diagnostic criteria have evolved considerably since the original description, through the 1990 NIH criteria, the 2003 Rotterdam consensus and the most recent 2023 International Evidence-based Guideline update.

The terms PCOD and PCOS are frequently used interchangeably in public discourse, though clinical literature generally uses PCOS to describe the internationally recognised endocrine syndrome. Scientific understanding requires precision: PCOS is characterised by a combination of anovulation, hyperandrogenism and/or polycystic ovarian morphology, not by the presence of ovarian cysts alone, and multiple ovarian follicles on ultrasound are not, by themselves, diagnostic.

02 / Global Burden

Global Statistics & Prevalence

Reliable prevalence data are essential to appropriately scale awareness, clinical services and research investment. PCOS represents a substantial and underrecognised global health burden.

Global PCOS Prevalence & Diagnostic Gap

Figure 1. Global PCOS Burden in Numbers (WHO 2023, Arch Gynecol Obstet 2024).

8–13%

Global prevalence among women of reproductive age (WHO)

~70%

Affected women remaining undiagnosed worldwide

65.77M

Prevalent PCOS cases globally in 2021 (89% rise since 1990)

03 / Diagnosis Criteria

The Rotterdam Diagnostic Criteria

The Rotterdam criteria (2003) require the presence of at least two of three defining features, following active exclusion of other androgen-excess or ovulatory disorders:

CRITERION 1

Oligo- or Anovulation

Irregular, delayed, or absent menstrual cycles reflecting chronic lack of regular ovulation.

CRITERION 2

Hyperandrogenism

Clinical signs (hirsutism, acne, androgenic alopecia) or biochemical elevation of serum androgens.

CRITERION 3

Polycystic Ovaries

Ultrasound appearance of ≥20 follicles per ovary or ovarian volume ≥10 ml (in adults).

Figure 2. Rotterdam Diagnostic Framework — Thyroid dysfunction, hyperprolactinaemia, and non-classic congenital adrenal hyperplasia must be ruled out before confirming diagnosis.

04 / Pathophysiology

The Pathophysiology of PCOS

PCOS pathophysiology centres on a self-reinforcing cycle between insulin resistance and androgen excess:

Insulin Resistance

↓

Compensatory Hyperinsulinaemia

↓

Stimulation of Ovarian & Adrenal Androgens

↓

Suppression of Hepatic SHBG (High Free Androgens)

↓

Follicular Arrest & Chronic Anovulation

Figure 3. The Insulin Resistance – Hyperandrogenism Cycle in PCOS: Explains why lifestyle and insulin-sensitising interventions improve both metabolic and reproductive outcomes.

05 / Diagnostics

Diagnostic Evaluation

A structured clinical assessment applies the Rotterdam criteria and excludes mimicking conditions:

Assessment	Clinical Purpose
Menstrual & Symptom History	Assesses cycle regularity, acne, hirsutism pattern, and age of onset
Serum Testosterone / Free Androgen Index	Confirms biochemical hyperandrogenism
TSH, Prolactin, 17-OHP	Excludes thyroid disease, hyperprolactinaemia, and adrenal hyperplasia
Pelvic Ultrasound	Assesses ovarian morphology, follicle count, and endometrial thickness
OGTT / Fasting Glucose & Insulin	Screens for insulin resistance and glucose intolerance
Fasting Lipid Panel	Assesses associated cardiometabolic and dyslipidemia risk

Diagnosis in adolescents requires particular caution, as irregular cycles and mild acne are common post-menarche and do not alone confirm PCOS.

06 / Red Flags

Red Flag Presentations Requiring Prompt Assessment

Clinical Warning Signs

Absence of menstruation for >3 months, or very heavy/prolonged bleeding — warrants evaluation to rule out endometrial hyperplasia from unopposed estrogen.
Rapid-onset or severe hirsutism/virilisation (voice deepening, cliteromegaly) — raises concern for an androgen-secreting tumour requiring urgent imaging.
Signs of marked insulin resistance (acanthosis nigricans, rapid central weight gain) — mandates comprehensive metabolic work-up.
Significant mood disturbance, anxiety, or depression — requires prompt mental health support.
Difficulty conceiving after 12 months (or 6 months if aged ≥35) — warrants dedicated fertility evaluation and referral.

07 / Modern Management

Modern Management of PCOS/PCOD

Management is individualized based on presenting concerns (metabolic, dermatological, menstrual, or fertility-related) and life stage:

First-Line Foundation

Lifestyle Modification

Structured dietary intervention, physical activity, and 5–10% weight loss significantly improve ovulation and insulin sensitivity.

Metabolic

Insulin Sensitisers

Metformin or other insulin-sensitising therapies for women with metabolic dysfunction or impaired glucose tolerance.

Hormonal

Cycle & Symptom Control

Combined oral contraceptives to restore regular withdrawal bleeds and suppress androgen-driven acne and hirsutism.

Fertility

Ovulation Induction

Letrozole as the first-line pharmacological treatment for anovulatory infertility, with assisted reproduction for non-responders.

Skin & Mind

Derm & Psychological Care

Anti-androgens for dermatological symptoms alongside dedicated screening and support for anxiety and depression.

08 / Long-Term Health

The Metabolic and Cardiovascular Connection

Women with PCOS, particularly hyperandrogenic phenotypes, face an approximately 2.5-fold increased risk of developing type 2 diabetes and elevated lifetime cardiovascular risk, independent of BMI.

Cardiometabolic Risks

Elevated prevalence of dyslipidemia, hypertension, endothelial dysfunction, and non-alcoholic fatty liver disease (MASLD).

Endometrial Protection

Chronic anovulation leads to continuous unopposed estrogen stimulation, elevating the long-term risk of endometrial hyperplasia and cancer if untreated.

09 / Ayurveda

Ayurvedic and Holistic Wellness Perspective

Ayurvedic literature correlates PCOS presentations with Artava Kshaya and related Yonivyapad, emphasizing Kapha-Vata imbalance, impaired Agni (metabolic fire), and Ama accumulation. Traditional management centers on Ahara (diet), Vihara (lifestyle), Vyayama (exercise), and Rasayana (rejuvenation).

Ayurvedic dietary science, weight support, and stress reduction provide valuable complementary metabolic support.

Safety Rule: Holistic strategies must never replace formal medical diagnosis, metabolic screening, or indicated fertility treatments.

10 / Panchakarma

Panchakarma: The Need for Responsible Integration

Panchakarma procedures directed at metabolic and menstrual disorders (such as structured Ahara, Udvartana, and mild individualized Basti protocols) require careful assessment.

Clinical Boundaries & Contraindications

Panchakarma is contraindicated during suspected or confirmed pregnancy or active fertility treatment cycles without specialist coordination. It must never be promoted as a cure for androgen-secreting tumours or as a substitute for ovulation induction in women actively pursuing conception.

11 / SR VAIDYA Framework

The SR VAIDYA Holistic Wellness Framework

A structured integrative educational pathway tailored for PCOS/PCOD care:

S SCREEN (Cycles & Signs)

R VERIFY (Rotterdam Criteria)

V REFER (Endo / Gynae)

A SUPPORT (Metabolic Lifestyle)

I MONITOR (Glucose & Lipids)

D EDUCATE (Self-Management)

Y-A FOLLOW UP (Long-Term Care)

Figure 4. The SR VAIDYA Integrative Framework for PCOS/PCOD Wellness Education (S-R-V-A-I-D-Y-A)

12 / Root-Factor Analysis

Root-Factor Analysis: A Scientifically Responsible Approach

PCOS does not arise from a single isolated defect. Root-Factor Analysis identifies interconnected contributing domains:

Insulin Resistance

Androgen Excess

Neuroendocrine / LH

Genetic Susceptibility

Lifestyle & Nutrition

Chronic Stress

Adiposity & MASLD

Figure 5. Root-Factor Analysis Wheel for PCOS/PCOD (Multidimensional Contributing Domains).

13 / Evidence

Evidence Grading of Key Claims

Claim	Evidence Grade	Scientific Basis
PCOS affects 8–13% of reproductive-aged women, ~70% undiagnosed	Strong	WHO Fact Sheet 2023; systematic reviews & meta-analyses
Insulin resistance is central to pathophysiology across most phenotypes	Strong	Extensive endocrinology and reproductive medicine literature
Weight loss of 5–10% improves ovulation and metabolic parameters	Strong	Multiple randomised controlled trials and Cochrane reviews
Letrozole is first-line therapy for ovulation induction in PCOS infertility	Strong	Large RCTs (Legro et al., 2014) and international guidelines
Structured yoga and stress reduction improve cycle regularity as adjuncts	Moderate	Emerging randomised trials; heterogeneous study designs
Specific Ayurvedic herbal formulations reverse PCOS comparably to standard care	Weak	Limited, small-sample trials; insufficient for treatment substitution
Panchakarma alone resolves androgen-secreting tumours or infertility	Weak / Unsupported	No robust clinical evidence; contraindicated as sole therapy

14 / Discussion

Discussion

PCOS care requires integration without exaggeration. Conventional medicine provides accurate diagnosis, metabolic therapy, hormonal cycle control, and ovulation induction, while holistic wellness empowers women through sustainable nutrition, exercise, and stress reduction to alleviate the substantial psychological and metabolic burden of the condition.

15 / Recommendations

Proposed Conference Recommendations

Encourage accurate application of Rotterdam criteria rather than diagnosing based on ultrasound findings alone.

Train wellness practitioners to recognise red-flag presentations requiring urgent endocrine or gynaecological referral.

Focus lifestyle interventions on long-term metabolic resilience and ovulatory health rather than claiming to cure PCOS.

Promote awareness to close the substantial ~70% global under-diagnosis gap highlighted by WHO.

Individualise Ayurvedic interventions and never delay indicated fertility treatment or metabolic screening.

Conduct ethically designed observational and controlled clinical studies of integrative lifestyle programmes in PCOS.

Study quality of life, psychological wellbeing, metabolic parameters, and menstrual outcomes without unsupported cure claims.

16 / Future Research

Future Research Proposal for SR VAIDYA

“Effect of a Structured Holistic Lifestyle Programme on Metabolic Parameters, Menstrual Regularity and Quality of Life in Women with PCOS Receiving Standard Medical Care.”

Study Type Prospective observational study or pilot randomised controlled trial.

Participants Women with Rotterdam-confirmed PCOS under active medical management (N = 100–130).

Standard Care Participants continue prescribed medical therapies throughout the study.

Duration 12-week intervention period.

Holistic Components Structured low-glycemic dietary guidance, physical activity, sleep hygiene, and stress-reduction yoga practices.

Primary Endpoints Change in menstrual cycle regularity and HOMA-IR (insulin resistance index) at 12 weeks.

Secondary Endpoints Quality-of-life scores, body weight, lipid profile, and anxiety/depression scales.

Important Principle Investigates structured lifestyle support as an adjunct to standard care rather than claiming to cure PCOS.

17 / Conclusion

Conclusion

PCOS/PCOD is the most common endocrine disorder among women of reproductive age, yet remains substantially underdiagnosed worldwide. Managing the complex interplay of insulin resistance, hyperandrogenism, ovulatory dysfunction, and psychological distress requires both precise medical evaluation and sustained lifestyle support.

SCREEN → VERIFY → REFER → SUPPORT → FOLLOW UP

MEDICAL DIAGNOSIS PROVIDES CLARITY.
LIFESTYLE PROVIDES FOUNDATION.
HOLISTIC WELLNESS PROVIDES SUPPORT.
RESPONSIBLE REFERRAL PROVIDES SAFETY.

Acknowledgement

The author acknowledges the importance of interdisciplinary dialogue between conventional medicine, gynaecology, endocrinology, reproductive medicine, Ayurveda, lifestyle medicine, and holistic wellness research in developing patient-centred and scientifically responsible approaches to PCOS/PCOD.

References

Key Scientific References

World Health Organization. (2023). Polycystic ovary syndrome [Fact sheet]. WHO Press.
Teede, H. J., et al. (2023). Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertility and Sterility, 120(4), 767–793.
Naeimeh, T., & colleagues. (2024). Global prevalence of polycystic ovary syndrome in women worldwide: A comprehensive systematic review and meta-analysis. Archives of Gynecology and Obstetrics, 310(3), 1303–1314.
Liu, J., et al. (2021). Measuring the global disease burden of polycystic ovary syndrome in 194 countries: Global Burden of Disease Study 2017. Human Reproduction, 36(4), 1108–1119.
Legro, R. S., et al. (2014). Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. New England Journal of Medicine, 371(2), 119–129.
Cooney, L. G., et al. (2017). High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: A systematic review and meta-analysis. Human Reproduction, 32(5), 1075–1091.
Moran, L. J., et al. (2011). Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews, 7, CD007506.

PCOD / PCOSand Holistic Wellness